Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.

Identifieur interne : 002780 ( PubMed/Corpus ); précédent : 002779; suivant : 002781

Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.

Auteurs : J M Armer ; B R Stewart

Source :

RBID : pubmed:21226414

English descriptors

Abstract

Breast cancer survivors are at life-time risk of developing lymphedema (LE). Quantification of LE has been problematic as the criteria used to identify lymphedema use various methods to assess changes in the volume of the affected limb. In part because of difficulties and variability in measurement and diagnosis, the reported incidence of LE varies greatly among women treated with surgery and radiation for breast cancer. The goal of this research was to describe the trends for LE occurrence over three points in time (12, 30, and 60 months) among breast cancer survivors using four diagnostic criteria based on three measurement techniques. Participants were enrolled following diagnosis of breast cancer but before surgery. Baseline limb volume and symptom assessment data were obtained. Participants were followed every 3 months for 12 months, then every 6 months thereafter for a total of 60 months. Limb volume changes (LVC) in both limbs were measured using three techniques: objectively by (a) circumferences at 4 cm intervals and (b) perometry and subjectively by (c) symptom experience via interview. Four diagnostic criteria for LE most often reported in the literature were used: (i) 2 cm circumferential change; (ii) 200 mL perometry LVC; (iii) 10% perometry LVC; and (iv) signs and symptoms (SS) report of limb heaviness and swelling, either 'now' or 'in the past year' (diagnostic criteria i-iii define increases/differences in limb volume from baseline and/or between the affected and non-affected limb). Standard survival analysis methods were applied to identify when the criteria corresponding to LE were met. Trends in LE occurrence are reported for preliminary analysis of data from 236 participants collected at 6-, 12-, 18-, 24-, 30-, and 60-months post-op. At 60 months post-treatment, LE incidence using the four criteria ranged from 43% to 94%, with 2 cm associated with the highest frequency for lymphedema occurrence and SS the lowest. Sixty-month trends are compared to earlier trends at 12- and 30-months, per criterion. These preliminary findings provide additional evidence that breast cancer survivors are at risk for developing LE beyond the first year following treatment. Cases of lymphedema continue to emerge through 60-months post-breast cancer surgery. This 60-month analysis supports the previous 12- and 30-month analyses in finding the 2 cm criteria to be the most liberal definition of LE. The self-report of heaviness and swelling, along with 10% LVC, represent the most conservative definitions (41% and 45%, respectively). Furthermore, the variety of criteria used to identify LE, along with the absence of baseline (pre-treatment) measurements, likely contribute to the wide range of LE incidence rates reported in the literature.

PubMed: 21226414

Links to Exploration step

pubmed:21226414

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.</title>
<author>
<name sortKey="Armer, J M" sort="Armer, J M" uniqKey="Armer J" first="J M" last="Armer">J M Armer</name>
<affiliation>
<nlm:affiliation>Sinclair School of Nursing, University of Missouri, Columbia, Missouri 65211, USA. armer@missouri.edu</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Stewart, B R" sort="Stewart, B R" uniqKey="Stewart B" first="B R" last="Stewart">B R Stewart</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:21226414</idno>
<idno type="pmid">21226414</idno>
<idno type="wicri:Area/PubMed/Corpus">002780</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002780</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.</title>
<author>
<name sortKey="Armer, J M" sort="Armer, J M" uniqKey="Armer J" first="J M" last="Armer">J M Armer</name>
<affiliation>
<nlm:affiliation>Sinclair School of Nursing, University of Missouri, Columbia, Missouri 65211, USA. armer@missouri.edu</nlm:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Stewart, B R" sort="Stewart, B R" uniqKey="Stewart B" first="B R" last="Stewart">B R Stewart</name>
</author>
</analytic>
<series>
<title level="j">Lymphology</title>
<idno type="ISSN">0024-7766</idno>
<imprint>
<date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Breast Neoplasms (complications)</term>
<term>Breast Neoplasms (mortality)</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Lymphedema (diagnosis)</term>
<term>Lymphedema (epidemiology)</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Incidence</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Breast cancer survivors are at life-time risk of developing lymphedema (LE). Quantification of LE has been problematic as the criteria used to identify lymphedema use various methods to assess changes in the volume of the affected limb. In part because of difficulties and variability in measurement and diagnosis, the reported incidence of LE varies greatly among women treated with surgery and radiation for breast cancer. The goal of this research was to describe the trends for LE occurrence over three points in time (12, 30, and 60 months) among breast cancer survivors using four diagnostic criteria based on three measurement techniques. Participants were enrolled following diagnosis of breast cancer but before surgery. Baseline limb volume and symptom assessment data were obtained. Participants were followed every 3 months for 12 months, then every 6 months thereafter for a total of 60 months. Limb volume changes (LVC) in both limbs were measured using three techniques: objectively by (a) circumferences at 4 cm intervals and (b) perometry and subjectively by (c) symptom experience via interview. Four diagnostic criteria for LE most often reported in the literature were used: (i) 2 cm circumferential change; (ii) 200 mL perometry LVC; (iii) 10% perometry LVC; and (iv) signs and symptoms (SS) report of limb heaviness and swelling, either 'now' or 'in the past year' (diagnostic criteria i-iii define increases/differences in limb volume from baseline and/or between the affected and non-affected limb). Standard survival analysis methods were applied to identify when the criteria corresponding to LE were met. Trends in LE occurrence are reported for preliminary analysis of data from 236 participants collected at 6-, 12-, 18-, 24-, 30-, and 60-months post-op. At 60 months post-treatment, LE incidence using the four criteria ranged from 43% to 94%, with 2 cm associated with the highest frequency for lymphedema occurrence and SS the lowest. Sixty-month trends are compared to earlier trends at 12- and 30-months, per criterion. These preliminary findings provide additional evidence that breast cancer survivors are at risk for developing LE beyond the first year following treatment. Cases of lymphedema continue to emerge through 60-months post-breast cancer surgery. This 60-month analysis supports the previous 12- and 30-month analyses in finding the 2 cm criteria to be the most liberal definition of LE. The self-report of heaviness and swelling, along with 10% LVC, represent the most conservative definitions (41% and 45%, respectively). Furthermore, the variety of criteria used to identify LE, along with the absence of baseline (pre-treatment) measurements, likely contribute to the wide range of LE incidence rates reported in the literature.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">21226414</PMID>
<DateCreated>
<Year>2011</Year>
<Month>01</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted>
<Year>2011</Year>
<Month>01</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0024-7766</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>43</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2010</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Lymphology</Title>
<ISOAbbreviation>Lymphology</ISOAbbreviation>
</Journal>
<ArticleTitle>Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.</ArticleTitle>
<Pagination>
<MedlinePgn>118-27</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>Breast cancer survivors are at life-time risk of developing lymphedema (LE). Quantification of LE has been problematic as the criteria used to identify lymphedema use various methods to assess changes in the volume of the affected limb. In part because of difficulties and variability in measurement and diagnosis, the reported incidence of LE varies greatly among women treated with surgery and radiation for breast cancer. The goal of this research was to describe the trends for LE occurrence over three points in time (12, 30, and 60 months) among breast cancer survivors using four diagnostic criteria based on three measurement techniques. Participants were enrolled following diagnosis of breast cancer but before surgery. Baseline limb volume and symptom assessment data were obtained. Participants were followed every 3 months for 12 months, then every 6 months thereafter for a total of 60 months. Limb volume changes (LVC) in both limbs were measured using three techniques: objectively by (a) circumferences at 4 cm intervals and (b) perometry and subjectively by (c) symptom experience via interview. Four diagnostic criteria for LE most often reported in the literature were used: (i) 2 cm circumferential change; (ii) 200 mL perometry LVC; (iii) 10% perometry LVC; and (iv) signs and symptoms (SS) report of limb heaviness and swelling, either 'now' or 'in the past year' (diagnostic criteria i-iii define increases/differences in limb volume from baseline and/or between the affected and non-affected limb). Standard survival analysis methods were applied to identify when the criteria corresponding to LE were met. Trends in LE occurrence are reported for preliminary analysis of data from 236 participants collected at 6-, 12-, 18-, 24-, 30-, and 60-months post-op. At 60 months post-treatment, LE incidence using the four criteria ranged from 43% to 94%, with 2 cm associated with the highest frequency for lymphedema occurrence and SS the lowest. Sixty-month trends are compared to earlier trends at 12- and 30-months, per criterion. These preliminary findings provide additional evidence that breast cancer survivors are at risk for developing LE beyond the first year following treatment. Cases of lymphedema continue to emerge through 60-months post-breast cancer surgery. This 60-month analysis supports the previous 12- and 30-month analyses in finding the 2 cm criteria to be the most liberal definition of LE. The self-report of heaviness and swelling, along with 10% LVC, represent the most conservative definitions (41% and 45%, respectively). Furthermore, the variety of criteria used to identify LE, along with the absence of baseline (pre-treatment) measurements, likely contribute to the wide range of LE incidence rates reported in the literature.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Armer</LastName>
<ForeName>J M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo>
<Affiliation>Sinclair School of Nursing, University of Missouri, Columbia, Missouri 65211, USA. armer@missouri.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stewart</LastName>
<ForeName>B R</ForeName>
<Initials>BR</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>R01 NR005342</GrantID>
<Acronym>NR</Acronym>
<Agency>NINR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 NR010293</GrantID>
<Acronym>NR</Acronym>
<Agency>NINR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1 R01 NR05342-01</GrantID>
<Acronym>NR</Acronym>
<Agency>NINR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Lymphology</MedlineTA>
<NlmUniqueID>0155112</NlmUniqueID>
<ISSNLinking>0024-7766</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2009 Dec;42(4):161-75</RefSource>
<PMID Version="1">20218084</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2776-81</RefSource>
<PMID Version="1">9874397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2008 Nov 10;26(32):5220-6</RefSource>
<PMID Version="1">18838708</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphat Res Biol. 2005;3(4):208-17</RefSource>
<PMID Version="1">16379589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Surg. 2004 Jan;187(1):69-72</RefSource>
<PMID Version="1">14706589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Nurs Res. 2003 Nov-Dec;52(6):370-9</RefSource>
<PMID Version="1">14639083</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Support Care Cancer. 2011 May;19(5):631-7</RefSource>
<PMID Version="1">20393753</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Invest. 2005;23(1):76-83</RefSource>
<PMID Version="1">15779870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1209-15</RefSource>
<PMID Version="1">12654429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2817-20</RefSource>
<PMID Version="1">9874404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Womens Health (Larchmt). 2003 Nov;12(9):921-30</RefSource>
<PMID Version="1">14670172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Patient Educ Couns. 2006 Apr;61(1):72-9</RefSource>
<PMID Version="1">16533679</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2009 Jan;113(2):383-91</RefSource>
<PMID Version="1">18297429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Clin Oncol. 2003 Jun;26(3):229-31</RefSource>
<PMID Version="1">12796589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Nurs Forum. 2008 Jan;35(1):57-63</RefSource>
<PMID Version="1">18192153</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2008 Mar;41(1):18-28</RefSource>
<PMID Version="1">18581955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Surg. 2003 Jan;90(1):76-81</RefSource>
<PMID Version="1">12520579</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2788-97</RefSource>
<PMID Version="1">9874399</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Lymphoedema. 2008 Oct 1;3(2):38-44</RefSource>
<PMID Version="1">20657749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2882-5</RefSource>
<PMID Version="1">9874417</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2002 Sep;75(1):51-64</RefSource>
<PMID Version="1">12500934</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Nurs Forum. 2004 Jan-Feb;31(1):97-104</RefSource>
<PMID Version="1">14722593</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Lymphoedema. 2009 Apr 1;4(1):14-18</RefSource>
<PMID Version="1">20182653</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS267225</OtherID>
<OtherID Source="NLM">PMC4520538</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>1</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2011</Year>
<Month>1</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">21226414</ArticleId>
<ArticleId IdType="pmc">PMC4520538</ArticleId>
<ArticleId IdType="mid">NIHMS267225</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002780 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002780 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:21226414
   |texte=   Post-breast cancer lymphedema: incidence increases from 12 to 30 to 60 months.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:21226414" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024